Compare CLNE & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLNE | ADCT |
|---|---|---|
| Founded | 2001 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 478.4M | 484.4M |
| IPO Year | 2006 | 2019 |
| Metric | CLNE | ADCT |
|---|---|---|
| Price | $2.15 | $4.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $3.49 | ★ $7.50 |
| AVG Volume (30 Days) | ★ 996.5K | 883.7K |
| Earning Date | 05-07-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 30.86 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $341,599,000.00 | $81,357,000.00 |
| Revenue This Year | $5.99 | $1.15 |
| Revenue Next Year | $17.00 | $86.93 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 14.85 |
| 52 Week Low | $1.30 | $1.05 |
| 52 Week High | $3.11 | $4.98 |
| Indicator | CLNE | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 37.85 | 45.91 |
| Support Level | $2.11 | $3.79 |
| Resistance Level | $2.26 | $4.63 |
| Average True Range (ATR) | 0.10 | 0.29 |
| MACD | -0.02 | -0.05 |
| Stochastic Oscillator | 12.31 | 5.96 |
Clean Energy Fuels Corp is a natural gas marketer and retailer operating in the United States and Canada. The company supplies compressed natural gas and liquefied natural gas for the United States (U.S.) and Canadian transportation markets. The majority of revenue is generated within the U.S. and mostly consists of compressed natural gas. The firm operates by purchasing natural gas from local utilities; compressing, cooling, or liquefying it at company-owned plants; and selling natural gas products through company-owned or customer-owned fueling stations. It also builds, operates, and maintains natural gas fueling stations for customers.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).